FDA Commissioner Scott Gottlieb has taken to Twitter again to state the FDA “continues to be concerned about branded companies creating confusion about the safety and effectiveness of biosimilars and we’ll take action if we determine a company is deliberately misleading the public about the safety of these important products.”
“For the last 50 years every major medical breakthrough can be traced back to investments in the NIH, which houses the National Cancer Institute (NCI),” said Wayne A. I. Frederick, interim chief executive officer of American Cancer Society and the American Cancer Society Cancer Action Network.
